Stephen Swisher
Overview
Explore the profile of Stephen Swisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, et al.
Nat Commun
. 2022 Apr;
13(1):1797.
PMID: 35379845
Methylthioadenosine phosphorylase, an essential enzyme for the adenine salvage pathway, is often deficient (MTAP) in tumors with 9p21 loss and hypothetically renders tumors susceptible to synthetic lethality by antifolates targeting...
12.
Bostock I, Hofstetter W, Mehran R, Rajaram R, Rice D, Sepesi B, et al.
J Thorac Dis
. 2022 Jan;
13(12):6848-6854.
PMID: 35070369
Background: Frequency of post-treatment surveillance is highly variable following curative resection of non-small cell lung cancer (NSCLC). We sought to characterize surveillance practices after lobectomy for early-stage NSCLC and to...
13.
Bostock I, Zhou N, Antonoff M, Blum Murphy M, Lin S, Maru D, et al.
Dis Esophagus
. 2021 Dec;
35(4).
PMID: 34897440
Neutrophilia is a potential biomarker for postoperative complications and oncologic outcomes. There is a paucity of data regarding neutrophilia in patients with esophageal adenocarcinoma. Our Institutional Database was queried for...
14.
Zorrilla-Vaca A, Feldman H, Antonoff M, Sepesi B, Hofstetter W, Rajaram R, et al.
Thorac Cardiovasc Surg
. 2021 Dec;
70(5):422-429.
PMID: 34894636
Introduction: Chest drains are placed following pulmonary resection to promote lung re-expansion. The superiority of two chest drains at preventing postoperative complications has not been established, and practice remains largely...
15.
Tang M, Abbas H, Negrao M, Ramineni M, Hu X, Hubert S, et al.
Nat Commun
. 2021 Dec;
12(1):7081.
PMID: 34873156
Histology plays an essential role in therapeutic decision-making for lung cancer patients. However, the molecular determinants of lung cancer histology are largely unknown. We conduct whole-exome sequencing and microarray profiling...
16.
Zorrilla-Vaca A, Rice D, Brown J, Antonoff M, Sepesi B, Hofstetter W, et al.
Surgery
. 2021 Nov;
171(2):504-510.
PMID: 34740455
Background: Enhanced Recovery After Surgery programs have been shown to effectively reduce opioid prescriptions at discharge after their implementation in several institutions, but little is known regarding the sustainability of...
17.
Zhao H, Misariu A, Ramirez-GarciaLuna J, Nobel T, Mueller C, Cools-Lartigue J, et al.
Ann Thorac Surg
. 2021 Apr;
113(4):1354-1360.
PMID: 33905733
Background: This study evaluated the safety and feasibility of combined resection for patients with synchronous pulmonary and esophageal cancer. Methods: Patients undergoing esophagectomy between 1997 and 2019 were identified from...
18.
Le X, Negrao M, Reuben A, Federico L, Diao L, McGrail D, et al.
J Thorac Oncol
. 2021 Jan;
16(4):583-600.
PMID: 33388477
Introduction: Lung adenocarcinomas harboring EGFR mutations do not respond to immune checkpoint blockade therapy and their EGFR wildtype counterpart. The mechanisms underlying this lack of clinical response have been investigated...
19.
Lam V, Zhang J, Wu C, Tran H, Li L, Diao L, et al.
J Thorac Oncol
. 2021 Jan;
16(4):601-609.
PMID: 33388476
Introduction: Plasma-based circulating tumor DNA (ctDNA) is an established biomarker for molecular profiling with emerging applications in disease monitoring in multiple tumor types, including, NSCLC. However, determinants of ctDNA shedding...
20.
Sitthideatphaiboon P, Galan-Cobo A, Negrao M, Qu X, Poteete A, Zhang F, et al.
Clin Cancer Res
. 2020 Dec;
27(6):1720-1733.
PMID: 33323404
Purpose: Radiotherapy with or without chemotherapy is a mainstay of treatment for locally advanced non-small cell lung cancer (NSCLC), but no predictive markers are currently available to select patients who...